Molecular Subgroups of Glioblastoma– an Assessment by Immunohistochemical Markers

Ádám Nagy, Ferenc Garzuly, Gergely Padányi, Iván Szűcs, Ádám Feldmann, Balázs Murnyák, T. Hortobágyi, B. Kálmán

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Comprehensive molecular characterization of and novel therapeutic approaches to glioblastoma have been explored as a result of advancements in biotechnologies. In this study, we aimed to bring basic research discoveries closer to clinical practice and ultimately incorporate molecular classification into the routine histopathological evaluation of grade IV gliomas. Integrated results of genome-wide sequencing, transcriptomic and epigenomic analyses by The Cancer Genome Atlas Network defined the classic, proneural, neural and mesenchymal subtypes of this tumor. In a retrospective cohort, we analyzed selected subgroup-defining molecular markers in formalin-fixed paraffin-embedded surgical specimens by immunohistochemistry. Quantitative and qualitative scores of marker expression were tested in hierarchical cluster analyses to evaluate segregations of the molecular subgroups, which then were correlated with clinical parameters including patients’ age, gender and overall survival. Our study has confirmed the separation of molecular glioblastoma subgroups with clear trends regarding clinical correlations. Future analyses in a larger, prospective cohort using similar methods are expected to facilitate the development of a molecular diagnostic panel that may complement routine histological work up and support prognostication as well as treatment decisions in glioblastoma.

Original languageEnglish
Pages (from-to)1-11
Number of pages11
JournalPathology and Oncology Research
DOIs
Publication statusAccepted/In press - Sep 26 2017

Fingerprint

Glioblastoma
Genome
Molecular Pathology
Atlases
Biotechnology
Epigenomics
Glioma
Paraffin
Formaldehyde
Cluster Analysis
Neoplasms
Immunohistochemistry
Survival
Therapeutics
Research

Keywords

  • Clinical setting
  • Glioblastoma
  • Molecular subgroups
  • Translation

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Oncology
  • Cancer Research

Cite this

Molecular Subgroups of Glioblastoma– an Assessment by Immunohistochemical Markers. / Nagy, Ádám; Garzuly, Ferenc; Padányi, Gergely; Szűcs, Iván; Feldmann, Ádám; Murnyák, Balázs; Hortobágyi, T.; Kálmán, B.

In: Pathology and Oncology Research, 26.09.2017, p. 1-11.

Research output: Contribution to journalArticle

Nagy, Ádám ; Garzuly, Ferenc ; Padányi, Gergely ; Szűcs, Iván ; Feldmann, Ádám ; Murnyák, Balázs ; Hortobágyi, T. ; Kálmán, B. / Molecular Subgroups of Glioblastoma– an Assessment by Immunohistochemical Markers. In: Pathology and Oncology Research. 2017 ; pp. 1-11.
@article{01b826fb7ba9488e84aa69ae9eebc13e,
title = "Molecular Subgroups of Glioblastoma– an Assessment by Immunohistochemical Markers",
abstract = "Comprehensive molecular characterization of and novel therapeutic approaches to glioblastoma have been explored as a result of advancements in biotechnologies. In this study, we aimed to bring basic research discoveries closer to clinical practice and ultimately incorporate molecular classification into the routine histopathological evaluation of grade IV gliomas. Integrated results of genome-wide sequencing, transcriptomic and epigenomic analyses by The Cancer Genome Atlas Network defined the classic, proneural, neural and mesenchymal subtypes of this tumor. In a retrospective cohort, we analyzed selected subgroup-defining molecular markers in formalin-fixed paraffin-embedded surgical specimens by immunohistochemistry. Quantitative and qualitative scores of marker expression were tested in hierarchical cluster analyses to evaluate segregations of the molecular subgroups, which then were correlated with clinical parameters including patients’ age, gender and overall survival. Our study has confirmed the separation of molecular glioblastoma subgroups with clear trends regarding clinical correlations. Future analyses in a larger, prospective cohort using similar methods are expected to facilitate the development of a molecular diagnostic panel that may complement routine histological work up and support prognostication as well as treatment decisions in glioblastoma.",
keywords = "Clinical setting, Glioblastoma, Molecular subgroups, Translation",
author = "{\'A}d{\'a}m Nagy and Ferenc Garzuly and Gergely Pad{\'a}nyi and Iv{\'a}n Szűcs and {\'A}d{\'a}m Feldmann and Bal{\'a}zs Murny{\'a}k and T. Hortob{\'a}gyi and B. K{\'a}lm{\'a}n",
year = "2017",
month = "9",
day = "26",
doi = "10.1007/s12253-017-0311-6",
language = "English",
pages = "1--11",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Molecular Subgroups of Glioblastoma– an Assessment by Immunohistochemical Markers

AU - Nagy, Ádám

AU - Garzuly, Ferenc

AU - Padányi, Gergely

AU - Szűcs, Iván

AU - Feldmann, Ádám

AU - Murnyák, Balázs

AU - Hortobágyi, T.

AU - Kálmán, B.

PY - 2017/9/26

Y1 - 2017/9/26

N2 - Comprehensive molecular characterization of and novel therapeutic approaches to glioblastoma have been explored as a result of advancements in biotechnologies. In this study, we aimed to bring basic research discoveries closer to clinical practice and ultimately incorporate molecular classification into the routine histopathological evaluation of grade IV gliomas. Integrated results of genome-wide sequencing, transcriptomic and epigenomic analyses by The Cancer Genome Atlas Network defined the classic, proneural, neural and mesenchymal subtypes of this tumor. In a retrospective cohort, we analyzed selected subgroup-defining molecular markers in formalin-fixed paraffin-embedded surgical specimens by immunohistochemistry. Quantitative and qualitative scores of marker expression were tested in hierarchical cluster analyses to evaluate segregations of the molecular subgroups, which then were correlated with clinical parameters including patients’ age, gender and overall survival. Our study has confirmed the separation of molecular glioblastoma subgroups with clear trends regarding clinical correlations. Future analyses in a larger, prospective cohort using similar methods are expected to facilitate the development of a molecular diagnostic panel that may complement routine histological work up and support prognostication as well as treatment decisions in glioblastoma.

AB - Comprehensive molecular characterization of and novel therapeutic approaches to glioblastoma have been explored as a result of advancements in biotechnologies. In this study, we aimed to bring basic research discoveries closer to clinical practice and ultimately incorporate molecular classification into the routine histopathological evaluation of grade IV gliomas. Integrated results of genome-wide sequencing, transcriptomic and epigenomic analyses by The Cancer Genome Atlas Network defined the classic, proneural, neural and mesenchymal subtypes of this tumor. In a retrospective cohort, we analyzed selected subgroup-defining molecular markers in formalin-fixed paraffin-embedded surgical specimens by immunohistochemistry. Quantitative and qualitative scores of marker expression were tested in hierarchical cluster analyses to evaluate segregations of the molecular subgroups, which then were correlated with clinical parameters including patients’ age, gender and overall survival. Our study has confirmed the separation of molecular glioblastoma subgroups with clear trends regarding clinical correlations. Future analyses in a larger, prospective cohort using similar methods are expected to facilitate the development of a molecular diagnostic panel that may complement routine histological work up and support prognostication as well as treatment decisions in glioblastoma.

KW - Clinical setting

KW - Glioblastoma

KW - Molecular subgroups

KW - Translation

UR - http://www.scopus.com/inward/record.url?scp=85029807859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029807859&partnerID=8YFLogxK

U2 - 10.1007/s12253-017-0311-6

DO - 10.1007/s12253-017-0311-6

M3 - Article

C2 - 28948518

AN - SCOPUS:85029807859

SP - 1

EP - 11

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

ER -